The Barostim HOPE4HF clinical trial will evaluate the effectiveness and safety of Barostim neo, a second generation implantable device that electrically activates the baroreceptors, the body’s natural blood pressure sensors that regulate heart function. The system is designed to signal the brain to relax the arteries to facilitate blood flow, slow the heart allowing more time for it to fill with blood, and prompt the kidneys to reduce fluid in the body, reducing the heart’s workload. This, in turn, is designed to improve heart function and reduce heart failure symptoms.
“Barostim Therapy initially was studied in more than 500 patients with excellent results,” said
Perfecting a device that can help the heart work more efficiently would be an important advance for the 5.1 million adults living with heart failure in the US. Statistics show that 670,000 new cases are diagnosed each year and more than 277,000 people die annually of the disease. In western
In heart failure, the heart cannot pump enough blood to support the body. Impaired heart function results in shortness of breath, exercise intolerance and fluid retention. Those with heart failure are six to nine times more likely to experience sudden cardiac death than their healthy counterparts.
Barostim neo is a pacemaker-like device consisting of two parts: a small pulse generator implanted under the collar bone which is connected by a think wire to a small lead implanted unilaterally either on the left or the right carotid artery. An external programmer is used by doctors to non-invasively transmit and regulate energy from the generator to the small lead.
Barostim neo is adjustable to each patient’s unique needs. The device operates automatically and continuously, eliminating the possibility of noncompliance with treatment recommendations.
Barostim neo was developed by
The device achieved promising clinical results in European studies. AGH and a handful of other elite US medical centers will be enrolling up to sixty patients in the American study.
To enroll, patients must have a left ventricular ejection fraction less than or equal to 35 percent and be classified as having New York Heart Association Class III Heart Failure.
For more information on the study, contact
The hospital’s broad scope of advanced capabilities in the treatment of heart failure offers patients access to cutting edge investigational therapies being explored in clinical trials, such as new medicines and implantable devices designed to more effectively monitor disease progression and treat conditions before they require hospitalization.
About the Allegheny Health Network:
Allegheny Health Network is an integrated healthcare delivery system serving the
Read the full story at http://www.prweb.com/releases/2013/10/prweb11251910.htm
Most Popular Stories
- Bipartisan Budget Deal Gets Key Support in House
- Bitcoin Clones Lurch Onto Financial Scene
- Clinton to Keynote Annual Simmons Leadership Conference
- Selena Gomez, Shakira Among Top Hispanic Searches
- GM to Stop Making Autos in Australia
- PhD Project Grooms Business Profs
- How Bitcoin and Other Cryptocurrencies Work
- It's Primary Time in Texas
- How to Survive a Subzero Stranding
- Pacific Trade Pact Delay Hinders U.S. Pivot to Asia